AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

664.582

+2.2270.34%

Number of Gainers:10

Number of Losers:11

Number of Flat:22

PE:- -

High:666.258

Open:660.539

Low:656.656

Close:662.355

Volume:13.90M

Turnover:37.50M

Market Cap:93.86B

Float Cap:90.54B

Loading ...

Botanix Pharmaceuticals Ltd - FY Net Loss Attributable A$69.8 Mln

THOMSON REUTERS

Invion Ltd - FY Prelim Revenues from Ordinary Activities A$384,707

THOMSON REUTERS

Invion Ltd - no Dividends Recommended or Declared During Current Financial Period

THOMSON REUTERS

Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up

MT Newswires Live

Starpharma FY Revenue AUD 12 Million

THOMSON REUTERS

Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million

THOMSON REUTERS

Starpharma Holdings Ltd-Preliminary Final Report

THOMSON REUTERS

PolyNovo Fiscal 2026 Earnings Down, Revenue Up

MT Newswires Live

Prescient Therapeutics Ltd-Share Purchase Plan Cleansing Notice

THOMSON REUTERS

Polynovo FY Revenues from Ordinary Activities A$150 Million

THOMSON REUTERS

3 ASX Growth Companies With Up To 32% Insider Ownership

Simply Wall St.

3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now

Simply Wall St.

Australia's Prescient Therapeutics Hits Near 2-Month Low on Discounted Raise

Prescient Therapeutics Launches Share Purchase Plan to Raise Up to AU$7 Million, Shares Fall 7%

MT Newswires Live

3 ASX Growth Stocks Backed By Strong Balance Sheets

Simply Wall St.

3 Penny Stocks With Stronger Balance Sheets Worth A Closer Look

Simply Wall St.

Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug

MT Newswires Live

Prescient Therapeutics - Launches Spp to Raise A$7 Mln at A$0.065 Per Share

THOMSON REUTERS

Prescient Therapeutics Ltd-Prescient Therapeutics Launches Share Purchase Plan for $7M

THOMSON REUTERS

Mesoblast Limited Expected to Post a Loss of 3 Cents a Share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK7508/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":664.5822,"timestamp":1788139372258,"preClose":662.35516,"halted":0,"volume":13904857,"delay":0,"changeRate":0.003362,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.227051,"latestTime":"08-31 11:22:52 AEST","open":660.5389,"high":666.2579,"low":656.6562,"amount":37502167,"amplitude":0.014496,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788156000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788134400000,1788156000000]],"turnoverRate":0.000545,"increases":11,"decrements":11,"flats":21,"marketCap":93861476742.5,"floatMarketCap":90543916392.375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":666.2579,"amplitude":0.014496,"preClose":662.35516,"low":656.6562,"latestPrice":664.5822,"volume":13904857,"delay":0,"open":660.5389,"prevYearClose":644.3692,"prevWeekClose":662.355,"prevMonthClose":488.077,"prevQuarterClose":464.145,"fiveDayClose":657.516,"twentyDayClose":493.047,"sixtyDayClose":409.453,"secType":"PLATE","market":"AU","turnoverRate":0.000545,"marketCap":93861476742.5,"floatMarketCap":90543916392.375,"timestamp":1788139372258,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":10,"down":11,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662795315","title":"Botanix Pharmaceuticals Ltd - FY Net Loss Attributable A$69.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795315?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730880,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BK7508","BOT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662953167","title":"Invion Ltd - FY Prelim Revenues from Ordinary Activities A$384,707","url":"https://stock-news.laohu8.com/highlight/detail?id=2662953167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662953167?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730865,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","BK7509","IVX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662311795","title":"Invion Ltd - no Dividends Recommended or Declared During Current Financial Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2662311795","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662311795?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730865,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0E3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","IVX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763421","title":"Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763421","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662763421?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:28","pubTimestamp":1787704117,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056768","title":"Starpharma FY Revenue AUD 12 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662056768?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:46","pubTimestamp":1787701578,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXTR2ZQF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662684667","title":"Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662684667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662684667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:27","pubTimestamp":1787700422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXQDJSS5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768110","title":"Starpharma Holdings Ltd-Preliminary Final Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662768110?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:24","pubTimestamp":1787700243,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUEGVMLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","SPL.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080750","title":"PolyNovo Fiscal 2026 Earnings Down, Revenue Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080750","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080750?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:46","pubTimestamp":1787698001,"startTime":"0","endTime":"0","summary":"PolyNovo (ASX:PNV) logged AU$0.0105 in earnings per share for fiscal 2026, compared with AU$0.0189 a year ago, a Wednesday filing showed.For the 12 months ended June 30, total revenue was AU$150 million versus AU$129.2 million previously, the Australia-listed medical technology company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PNV.AU","BK7508","BK7126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750700","title":"Prescient Therapeutics Ltd-Share Purchase Plan Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662750700?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:46","pubTimestamp":1787697960,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUEWR71Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PTX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757459","title":"Polynovo FY Revenues from Ordinary Activities A$150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757459?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:56","pubTimestamp":1787694988,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXWSNSJ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PNV.AU","BK7126","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662575087","title":"3 ASX Growth Companies With Up To 32% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2662575087","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662575087?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:08","pubTimestamp":1787684893,"startTime":"0","endTime":"0","summary":"As the Australian Securities Exchange (ASX) prepares for a strong start, buoyed by positive corporate reporting and declining oil prices, investors are keenly observing market dynamics amid global trade tensions and energy sector shifts. In this environment, growth companies with substantial insider ownership can offer intriguing opportunities as they often signal confidence in the company's potential amidst evolving economic landscapes.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-frs/forrestania-resources-shares/news/3-asx-growth-companies-with-up-to-32-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-frs/forrestania-resources-shares/news/3-asx-growth-companies-with-up-to-32-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QFN.AU","ZYAU.AU","GIVE.AU","IISV.AU","BK7096","AEM.AU","BK7023","STW.AU","OZR.AU","SKS.AU","XKO.AU","FRS.AU","WZR.AU","IOZ.AU","BBOZ.AU","BK7508","BK7110","BK4141","BK7062","XJO.AU","VAP.AU","SLF.AU","BK7036","IMLC.AU","MFG.AU","BK4526","BK7095","BK7104","XAO.AU","IIGF.AU","BK4543","QRE.AU","DACE.AU","PDI.AU","AWJ.AU","TTT.AU","GEAR.AU","E200.AU","ASX","AR1.AU","AV1.AU","OZF.AU","BK7094","SPL.AU","AYA.AU","EIGA.AU","VAS.AU","ASX.AU","BK7039","BEAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662375941","title":"3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2662375941","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662375941?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:25","pubTimestamp":1787671538,"startTime":"0","endTime":"0","summary":"When central banks keep liquidity flowing, like the PBoC is doing through reverse repos and a sizable MLF, it highlights how dependent markets are on confidence and clear decision makers. Founder led companies tap into that same idea. You get leaders with skin in the game who are often wired for long term resilience. This article highlights three founder led stocks from our screener that fit that mindset today.\nThe stocks in this article are just a sample, and the full founder led screen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-australian-stocks-retail-investors-are-trackin-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-australian-stocks-retail-investors-are-trackin-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["STW.AU","FLT.AU","BK7042","ZYAU.AU","BK7043","BEAR.AU","BK7067","OZR.AU","DACE.AU","EIGA.AU","IIGF.AU","BK7070","GEAR.AU","IISV.AU","VAP.AU","BK7046","GIVE.AU","ISBC","BK7511","QFN.AU","BBOZ.AU","VAS.AU","QRE.AU","MAQ.AU","XAO.AU","XKO.AU","BK4211","MQG.AU","XJO.AU","IOZ.AU","IMLC.AU","E200.AU","BK7501","MSB.AU","BK7508","SLF.AU","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662478598","title":"Australia's Prescient Therapeutics Hits Near 2-Month Low on Discounted Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2662478598","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662478598?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:57","pubTimestamp":1787633876,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics hits near 2-month low on discounted raise** Shares of Australia's Prescient TherapeuticsPTX.AXfall as much as 4.2%, their lowest level since July 2** Shares hit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL6N44M092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662785801","title":"Prescient Therapeutics Launches Share Purchase Plan to Raise Up to AU$7 Million, Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662785801","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662785801?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:28","pubTimestamp":1787632124,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  launched a share purchase plan  to raise up to AU$7 million, with new fully paid ordinary shares to be issued at AU$0.065 per share, according to a Tuesday Australian bourse filing.The company said the issue price represents an 18.8% discount to the volume-weighted average price over the 10 trading days before the SPP was disclosed and a 9.7% discount to the last price.The company's shares fell 7% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTX.AU","BK4007","BK4139","LENZ","BK4539","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662785004","title":"3 ASX Growth Stocks Backed By Strong Balance Sheets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662785004","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662785004?lang=en_us&edition=fundamental","pubTime":"2026-08-25 11:25","pubTimestamp":1787628355,"startTime":"0","endTime":"0","summary":"Eurozone consumer confidence has reached a new high for 2026, and services activity remains solid. That points to households that feel more secure and are still spending, which can support companies with healthy balance sheets and clear earnings growth potential. The Healthy High Growth Potential screener filters for exactly those kinds of stocks. This article highlights three of the strongest candidates worth having on your radar now.\nThe stocks covered below are just a sample of this theme...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/3-asx-growth-stocks-backed-by-strong-balance-sheets","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/3-asx-growth-stocks-backed-by-strong-balance-sheets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7506","BK7067","BK7104","BK7095","BK7508","LYC.AU","MSB.AU","WGX.AU","BK7501","BK7507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074672","title":"3 Penny Stocks With Stronger Balance Sheets Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074672","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074672?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:37","pubTimestamp":1787618237,"startTime":"0","endTime":"0","summary":"With global bond yields at multi year highs and borrowing costs rising, many investors are rethinking how much risk they want to take on. That is where the Financially Fit Penny Stocks screener can be useful. It filters for low priced stocks with healthier balance sheets that may handle tighter financial conditions better than weaker peers. This article highlights three of the most interesting ideas from that list.\nThe three stocks below are just a starting sample. The full Financially Fit...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/3-penny-stocks-with-stronger-balance-sheets-worth-a-closer-l-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/3-penny-stocks-with-stronger-balance-sheets-worth-a-closer-l-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SIG.AU","BEGS","BK7506","GLTR","GOAU","BK4581","XBI","GBUG","BK7103","PICK","XME","BK4588","UYM","LABU","ALK.AU","BK4535","BK7104","MSB.AU","BK7508","BK7067","BK4585","BK7501","XLV","CEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204730","title":"Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:10","pubTimestamp":1787616632,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said the European Commission gave marketing authorization for Daybu, or trofinetide, for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older to its exclusive global licensee for trofinetide, Acadia Pharmaceuticals, according to a Tuesday Australian bourse filing.Daybu is now authorized to be marketed in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, per the filing.Under the companies' license agreement, for Europe, Neuren is entitled to receive $35 million following first commercial sale, potential sales milestone payments of up to $170 million on achievement of escalating annual net sales thresholds, and tiered royalties from mid-teens to low-20s percentage of net sales.Acadia earlier said that a commercial launch in Germany is expected in the December quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620101","title":"Prescient Therapeutics - Launches Spp to Raise A$7 Mln at A$0.065 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620101?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:06","pubTimestamp":1787612777,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUE3XTG7J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201019","title":"Prescient Therapeutics Ltd-Prescient Therapeutics Launches Share Purchase Plan for $7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201019","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201019?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:06","pubTimestamp":1787612777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUE3XTG7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PTX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662948201","title":"Mesoblast Limited Expected to Post a Loss of 3 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2662948201","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662948201?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:32","pubTimestamp":1787610724,"startTime":"0","endTime":"0","summary":"Mesoblast Limited <MESO.OQ> expected to post a loss of3cents a share - Earnings PreviewMesoblast LimitedMESO.OQ,MESO.Ois expected to  report resultson August 26 for the period ending March 31 2026The Melbourne Victoria-based  company is expected to report revenue of $33.277 million, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for Mesoblast Limited is for a loss of 3 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Mesoblast Limited is $35.00, about 105.9% above its last closing price of $17.00This summary was machine generated August 24 at 22:31 GMT.  All figures in US dollars unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL8N44L1QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","MESO","BK7501","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":142,"code":"91000000","status":"200"}]}}